Can we vaccinate against Type 1 diabetes?

F1000 Biology Reports

Volumn 4, Issue 1, 2012, Pages

  Peakman, Mark ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; AUTOIMMUNITY; BLOOD ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; PROPHYLAXIS; VACCINATION;

EID: 84868108174     PISSN: 17404118     EISSN: 1757594X     Source Type: Journal    
DOI: 10.3410/B4-19     Document Type: Article

References (61)

1. Skowera A, Ellis RJ, Varela-Calvino R, Arif S, Huang GC, Van-Krinks C, Zaremba A, Rackham C, Allen JS, Tree TI, Zhao M, Dayan CM, Sewell AK, Unger WW, Drijfhout JW, Ossendorp F, Roep BO, Peakman M: CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008, 118:3390-402.
2. Simpson E: Special regulatory T-cell review: Regulation of immune responses-examining the role of T cells. Immunology 2008, 123:13-6. (Pubitemid 350256011)
3. Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD: Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol 2008, 28(Suppl 1):S11-9.
4. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA: Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54:1407-14. (Pubitemid 40586671)
5. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI: Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-9. (Pubitemid 40105099)
6. Glisic-Milosavljevic S, Waukau J, Jailwala P, Jana S, Khoo HJ, Albertz H, Woodliff J, Koppen M, Alemzadeh R,HagopianW,Ghosh S: At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS One 2007, 2:e146.
7. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH: The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008, 181:7350-55.
8. Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RD, Peakman M, Tree TI: Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 2008, 154:353-9.
9. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, Nano R, Olek S, Maffi P, Scavini M, Secchi A, Staudacher C, Bonifacio E, Battaglia M: Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60:2903-13.
10. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, Jones R, Ring SM, McArdle W, Pembrey ME, Strachan DP, Dunger DB, Twells RC, Clayton DG, Todd JA: Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:773-9. (Pubitemid 40563099)
11. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T: Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27. (Pubitemid 44116697)
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-64.
13. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmuller U, Baron U, Olek S, Bluestone JA, Brusko TM: Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186:3918-26.
14. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH: Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59:407-15.
15. Bayer AL, Yu A, Adeegbe D, Malek TR: Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 2005, 201:769-77. (Pubitemid 40403028)
16. Burchill MA, Yang J, Vang KB, Farrar MA: Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007, 114:1-8.
17. Setoguchi R, Hori S, Takahashi T, Sakaguchi S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005, 201:723-35. (Pubitemid 40395118)
18. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-51. (Pubitemid 41541792)
19. D'Cruz LM, Klein L: Development and function of agonistinduced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005, 6:1152-9. (Pubitemid 41541793)
20. Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, Pekalski M, Bell GL, Nutland S, Peakman M, Todd JA, Wicker LS, Tree TI: Type 1 Diabetes-Associated IL2RA Variation Lowers IL-2 Signaling and Contributes to Diminished CD4+CD25+ Regulatory T Cell Function. J Immunol 188:4644-53.
21. Peakman M, Dayan CM: Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology 2001, 104:361-6. (Pubitemid 34037827)
22. Larche M, Wraith DC: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005, 11:S69-76. (Pubitemid 40562306)
23. Sabatos-Peyton CA, Verhagen J, Wraith DC: Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 2010.
24. Sabatos-Peyton CA, Verhagen J, Wraith DC: Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 22:609-15.
25. Wraith DC, Nicolson KS, Whitley NT: Regulatory CD4+ T cells and the control of autoimmune disease. Curr Opin Immunol 2004, 16:695-701. (Pubitemid 39423656)
26. Noon L: Prophylactic inoculation against hay fever. Lancet 1911, 1:1572-3.
27. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern LJ, Gronlund H, van Hage M, Reynolds CJ, Boyton RJ, Cobbold SP, Kay AB, Altmann DM, Lloyd CM, Larché M: Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009, 206:1535-47.
28. Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761-71. (Pubitemid 44453462)
29. Larche M: Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006, 18:745-50. (Pubitemid 44635181)
30. Larche M: Immunotherapy with allergen peptides. Allergy Asthma Clin Immunol 2007, 3:53-9. (Pubitemid 47262602)
31. Larche M: Peptide immunotherapy. Immunol Allergy Clin North Am 2006, 26:321-32, viii. (Pubitemid 44262083)
32. Karges W, Pechhold K, Al Dahouk S, Riegger I, Rief M, Wissmann A, Schirmbeck R, Barth C, Boehm BO: Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes 2002, 51:3237-44. (Pubitemid 35246970)
33. Todd JA: Etiology of type 1 diabetes. Immunity 32:457-67.
34. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-63. (Pubitemid 38544189)
35. Tree TI, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, Peakman M: Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59:1451-60.
36. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigenspecific T-cell responses and prevents colitis. Nature 1997, 389:737-42. (Pubitemid 27458961)
37. Roep BO, Peakman M: Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2:a007781.
38. Peakman M, von Herrath M: Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010, 59:2087-93.
39. Bellmann K, Kolb H, Rastegar S, Jee P, Scott FW: Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats. Diabetologia 1998, 41:844-7. (Pubitemid 28313720)
40. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliot JF, Leiter EH: Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta-cell antigens. Diabetes 1997, 46:1975-82. (Pubitemid 27512083)
41. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, Raine CS, Hauser SL: Late complications of immune deviation therapy in a nonhuman primate. Science 1996, 274:2054-7. (Pubitemid 27020694)
42. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-75.
43. Steinman L, Merrill JT, McInnes IB, Peakman M: Optimization of current and future therapy for autoimmune diseases. Nat Med 2012, 18:59-65.
44. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R: GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-20.
45. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E: Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28:1068-76. (Pubitemid 40616615)
46. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR: T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999, 12:121-9. (Pubitemid 29130589)
47. www.andromedabio.com
48. Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M: Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009, 155:156-65.
49. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P: Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010, 34:408-15.
50. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipila JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O: Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372:1746-55.
51. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli PD: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990, 347:151-6. Erratum in: Nature 1990, 347:782. Camilli, PD.
52. Wherrett DK, Bundy B, Becker DJ,DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet GAD Study Group: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378:319-27.
53. Ludvigsson J, Krisky D, Casas R, Battelino T, Castano L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J: GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366:433-42.
54. Peakman M, von Herrath M: Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 59: 2087-93.
55. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, Dotta F, Rottiers P, Gysemans C, Mathieu C: Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122:1717-25.
56. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006, 116:1371-81.
57. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group: Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, doubleblind, placebo-controlled trial. Lancet 378:412-9.
58. Clemente-Casares X, Tsai S, Yang Y, Santamaria P: Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach? J MolMed (Berl) 89:733-42.
59. Daniel C, Weigmann B, Bronson R, von Boehmer H: Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med 208:1501-10.
60. Roep BO, Peakman M: Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 10:145-52.
61. Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, Vives-Pi M, Powrie J, Tree T, Marchetti P, Huang GC, Gurzov EN, Pujol-Borrell R, Eizirik DL, Peakman M: Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011, 60:2112-9.